HealthEquity, Inc. (HQY) News

HealthEquity, Inc. (HQY): $71.73

-1.77 (-2.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter HQY News Items

HQY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HQY News Highlights

  • HQY's 30 day story count now stands at 14.
  • Over the past 17 days, the trend for HQY's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about HQY are LI, AMN and UL.

Latest HQY News From Around the Web

Below are the latest news stories about HEALTHEQUITY INC that investors may wish to consider to help them evaluate HQY as an investment opportunity.

Zacks Industry Outlook Highlights HealthEquity, AMN Healthcare and ModivCare

HealthEquity, AMN Healthcare and ModivCare have been highlighted in this Industry Outlook article.

Yahoo | September 15, 2022

3 Medical Services Stocks Braving Near-Term Industry Headwinds

The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, AMN and MODV are set to gain the most. However, staffing shortages may disrupt the trend.

Yahoo | September 14, 2022

HealthEquity rises after company raises full-year revenue forecast, beats estimates

Barrington Remains a Buy on Healthequity (HQY)

Barrington analyst Alexander Paris reiterated a Buy rating on Healthequity (HQY - Research Report) today and set a price target of $75.00. The company's shares opened today at $66.30.Paris covers the Services sector, focusing on stocks such as Franklin Covey Company, Lincoln Edu, and Universal Technical Institute. According to TipRanks, Paris has an average return of 15.6% and a 54.55% success rate on recommended stocks. In addition to Barrington, Healthequity also received a Buy from BTIG's David Larsen in a report issued yesterday. However, today, Goldman Sachs maintained a Sell rating on Healthequity (NASDAQ: HQY).See the top stocks recommended by analysts >>HQY market cap is currently $5.

Ryan Adist on TipRanks | September 7, 2022

HealthEquity (HQY) Q2 Earnings Lag Estimates, Margins Down

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in majority of its segments, in the second quarter of fiscal 2023.

Yahoo | September 7, 2022

HealthEquity (HQY) Q2 2023 Earnings Call Transcript

HQY earnings call for the period ending June 30, 2022.

Yahoo | September 7, 2022

HealthEquity (HQY) Misses Q2 Earnings Estimates

HealthEquity (HQY) delivered earnings and revenue surprises of -2.94% and 1.35%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | September 6, 2022

Edited Transcript of HQY.OQ earnings conference call or presentation 6-Sep-22 8:30pm GMT

Q2 2023 Healthequity Inc Earnings Call

Yahoo | September 6, 2022

HealthEquity Reports Second Quarter Ended July 31, 2022 Financial Results

Highlights of the second quarter include: Revenue of $206.1 million, an increase of 9% compared to $189.1 million in Q2 FY22.Net loss of $10.7 million, compared to $3.8 million in Q2 FY22, with non-GAAP net income of $28.1 million, a decrease of 16% compared to $33.4 million in Q2 FY22.Net loss per diluted share of $0.13, compared to $0.05 in Q2 FY22, with non-GAAP net income per diluted share of $0.33, compared to $0.40 in Q2 FY22.Adjusted EBITDA of $67.0 million, an increase of 2% compared to

Yahoo | September 6, 2022

Healthequity (HQY) Receives a Buy from Barrington

In a report released today, Alexander Paris from Barrington reiterated a Buy rating on Healthequity (HQY - Research Report), with a price target of $75.00. The company's shares closed yesterday at $65.71.Paris covers the Services sector, focusing on stocks such as Lincoln Edu, Universal Technical Institute, and American Public Education. According to TipRanks, Paris has an average return of 16.1% and a 55.67% success rate on recommended stocks. Healthequity has an analyst consensus of Moderate Buy, with a price target consensus of $73.14, representing an 11.31% upside. In a report released on August 30, SVB Securities also reiterated a Buy rating on the stock with a $76.00 price target.

Austin Angelo on TipRanks | September 2, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4153 seconds.